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stent (DES) placement.
Methods: All available material from our autopsy stent registry with duration of
implant >30 days to include a total of 384 cases (mean age¼6113 years, 287 male)
with 614 stented lesions in native coronary arteries (BMS¼266 [median, 832 days],
1st-gen DES¼285 [383 days], and 2nd-gen DES¼63 lesions [210 days]) were
pathologically evaluated for the involvement of neoatherosclerosis in stent thrombosis
and restenosis.
Results: The prevalence of VLST (>1 year) was greater in 1st-gen DES (19%) as
compared with BMS (3%) and 2nd-gen DES (0%), where in-stent plaque rupture from
neoatherosclerosis accounted for 83% of VLST in BMS (5 of 6) and 15% of VLST in
1st-gen DES (5 of 33). The involvement of neoatherosclerosis in VLST increased with
time; for duration of implants >3 years, all VLST in BMS (5 of 5) and 33% of VLST
in 1st-gen DES (4 of 12) were attributed to in-stent rupture. VLST from in-stent
rupture occurred earlier in 1st-gen DES (1434579 days) vs. BMS (2376545 days).
Of the 10 lesions with in-stent rupture, only 4 (BMS¼3, 1st-gen DES¼1) had in-stent
restenosis. In BMS, restenosis with underlying neoatherosclerosis was observed only
>3 years, and neoatherosclerosis accounted for 38% of BMS restenosis >3 years. In
contrast, both 1st- and 2nd-gen DES showed restenosis with neoatherosclerosis even
1 year. While only limited cases were available for 2nd-gen DES >1 year, 1st-gen
DES showed increased involvement of neoatherosclerosis in restenosis over time,
accounting for 31% of restenosis between 1 and 3 years and 78% of restenosis
>3 years.
Conclusions: Substantial involvement of neoatherosclerosis in late stent failure is
observed in both BMS and DES, which increases over time.
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Background: Noninferiority of biolimus-eluting stent (BES, Nobori) to everolimus-
eluting stent (EES, Xience) in clinical outcomes of drug-eluting stent (DES) im-
plantation has been reported; however, the difference in long-term clinical and
angiographic outcomes between them in the real world was little known. We aimed to
compare the two-year clinical and angiographic outcomes between EES and BES.
Methods: From 2010 to 2012, 4754 lesions received DES implantation: EES, 3391
lesions and BES, 1363 lesions. Midterm angiographic follow-up was scheduled at 8
months and late-term at 20 months. Target lesion revascularization (TLR) was deﬁned
as clinically or angiographically driven TLR. The TLR rate was calculated by the
Kaplan-Meier methods and compared by the long-rank test. Additionally, we analyzed
2978 lesions (EES, 1153 and BES 825) after late-term follow-up, which were free
from in-stent restenosis (ISR) and TLR at mid-term follow-up. ISR was deﬁned as
restenosis >50% and late catch-up phenomenon as the ﬁrst ISR over one year after
DES implantation.
Results: Between EES and BES, there were no signiﬁcant differences in the rates of
midterm restenosis (7.9% vs. 8.6%, p¼0.51), late catch-up phenomenon (5.8% vs.
4.4%, p¼0.13), and TLR (6.4% vs. 7.0%, log-rank p¼0.47). Meanwhile, in a sub-
group analysis, BES was signiﬁcantly more effective than EES to prevent late catch-
up phenomenon in lesion length 30 mm and ostial lesion in the right coronary artery
(see ﬁgure).Conclusions: The treatment effect on late catch-up phenomenon compared between
BES and EES implantations could depend on speciﬁc lesion characteristics.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/CoTCT-657
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Background: One of the hypothesized long-term clinical beneﬁts of Absorb BVS
(Abbott Vascular, Santa Clara, CA) is plaque regression and stabilization (reduction in
necrotic and lipid composition). This could also potentially mitigate in-stent
neoatherosclerosis, a late adverse effect that may be responsible for recurrent acute
coronary episodes. We present interim 1-year imaging evaluation (from an ongoing
4-year longitudinal study) of neointimal characteristics after coronary placement of
Absorb BVS in an atherosclerotic familial hypercholesterolemic (FH) swine model.
Methods: After 1 week of hypercholesterolemic diet, coronary arteries were balloon-
injured. After next 20 weeks on diet, injured segments were implanted with BVS (n¼
23) and everolimus-eluting metallic stents (EES, n¼11). Interim angiography, IVUS
and OCT were performed again at 1 year. OCT analysis included previously published
qualitative neointimal tissue assessment according to its pattern of backscatter and
optical intensity (homogeneous, heterogeneous or layered).
Results: At 1-year, all the scaffolds/stents were well apposed, widely patent and fully
covered with neointima. The scaffold thickness remained unchanged from baseline. The
percentage of OCT cross-sections with homogeneous pattern (previously linked to more
ﬁbrotic and less inﬂammatory histopathologic appearance) was signiﬁcantly higher in
BVS than EES (60% vs. 38%, p< 0.05). Also, the incidence of calcium around struts
trended lower for BVS (13.0%vs. 36.4%p¼0.11). Plaque tissue characterization (iMAP-
IVUS, Boston Scientiﬁc) showed lower absolute (0.200.17 mm2) and relative (63%)
lipid component area inBVSvs.EES(0.350.24mm2and83%, respectively, p<0.05).
Conclusions: One year after implantation in the familial hypercholesterolemic (FH)
swine model, the appearance of neointima by endovascular imaging suggests a more
stable and mature composition in BVS than in the EES, yet with less calciﬁcation.
This ongoing study is hoped to provide serial annual insights out to 4 years into the
long-term arterial response to BVS and EES in experimental atherosclerotic setting.
TCT-658
The Mechanism and Pattern of In-Stent Restenosis Among Bare Metal,
1st Generation, and 2nd Generation Drug-Eluting Stents: An Intravascular
Ultrasound Study
Kosaku Goto1, Zhijing Zhao1, MITSUAK I. MATSUMURA2, Tomotaka Dohi3,
Nobuaki Kobayashi4, Ajay J. Kirtane5, Manish Parikh6, Martin Leon1,
Jeffrey W. Moses7, Gary S. Mintz8, Akiko Maehara9
1Cardiovascular Research Foundation, New York, NY, 2Kobe Red Cross Hospital,
Kobe, Hyogo, 3Columbia University Medical Center and Cardiovascular Research
Foundation, New York, United States, 4Columbia University Medical Center,
Cardiovascular Research Foundation, New York, NY, 5Columbia University /
Cardiovascular Research Foundation, New York, United States, 6Columbia
University, New York, USA, 7Columbia University Medical Center and the
Cardiovascular Research Foundation, New York, NY, 8Cardiovascular Research
Foundation, Washington, United States, 9Cardiovascular Reserach Foundation and
Columbia University Medical Center, New York, United States
Background: The mechanism and patterns of in-stent restenosis (ISR) comparing
bare metal stents (BMS) and 1st and 2nd generation drug-eluting stent (DES) as
evaluated by intravascular ultrasound (IVUS) have not been well delineated.
Methods: IVUS evaluation of in-stent restenosis (ISR) included core-lab based
assessments of morphology including ISR pattern (focal [< 10 mm] vs diffuse
[10 mm]), and/or any associated mechanical complication.
Results: There were 298 ISR lesions including 52 BMS, 73 sirolimus-eluting stents
(SES), 52 paclitaxel-eluting stents (PES), 16 zotarolimus-eluting stents (ZES), and
105 everolimus-eluting stent (EES) (Table). Mean pt age was 66.71.1 yrs, 74% were
male, 48.7% had diabetes mellitus, and 48.7% presented with acute coronary syn-
drome. BMS restenosis presented later (5.85.6 yrs) with more intimal hyperplasia.
Although reference lumen areas were similar among BMS and 1st and 2nd generation
DES, restenotic DES were longer and more often underexpanded with associated stent
fracture that was not seen in restenotic BMS.ronary Lesions - In-stent Restenosis B191
